20°C / 22°C
  • Tue
  • 26°C
  • 14°C
  • Wed
  • 28°C
  • 15°C
  • Thu
  • 23°C
  • 15°C
  • Fri
  • 25°C
  • 14°C
  • Sat
  • 27°C
  • 16°C
  • Sun
  • 29°C
  • 14°C
  • Tue
  • 20°C
  • 13°C
  • Wed
  • 21°C
  • 13°C
  • Thu
  • 21°C
  • 14°C
  • Fri
  • 24°C
  • 14°C
  • Sat
  • 20°C
  • 14°C
  • Sun
  • 21°C
  • 13°C
  • Tue
  • 29°C
  • 16°C
  • Wed
  • 29°C
  • 16°C
  • Thu
  • 25°C
  • 16°C
  • Fri
  • 26°C
  • 16°C
  • Sat
  • 28°C
  • 17°C
  • Sun
  • 29°C
  • 17°C
  • Tue
  • 31°C
  • 17°C
  • Wed
  • 32°C
  • 16°C
  • Thu
  • 26°C
  • 16°C
  • Fri
  • 28°C
  • 16°C
  • Sat
  • 29°C
  • 17°C
  • Sun
  • 29°C
  • 16°C
  • Tue
  • 23°C
  • 18°C
  • Wed
  • 22°C
  • 17°C
  • Thu
  • 25°C
  • 18°C
  • Fri
  • 24°C
  • 19°C
  • Sat
  • 26°C
  • 20°C
  • Sun
  • 26°C
  • 20°C
  • Tue
  • 19°C
  • 14°C
  • Wed
  • 19°C
  • 13°C
  • Thu
  • 20°C
  • 12°C
  • Fri
  • 20°C
  • 14°C
  • Sat
  • 21°C
  • 15°C
  • Sun
  • 21°C
  • 15°C
  • Tue
  • 22°C
  • 9°C
  • Wed
  • 26°C
  • 8°C
  • Thu
  • 23°C
  • 10°C
  • Fri
  • 28°C
  • 10°C
  • Sat
  • 23°C
  • 12°C
  • Sun
  • 23°C
  • 11°C
  • Tue
  • 17°C
  • 12°C
  • Wed
  • 21°C
  • 11°C
  • Thu
  • 19°C
  • 12°C
  • Fri
  • 22°C
  • 13°C
  • Sat
  • 20°C
  • 14°C
  • Sun
  • 19°C
  • 13°C
  • Tue
  • 31°C
  • 17°C
  • Wed
  • 30°C
  • 18°C
  • Thu
  • 26°C
  • 17°C
  • Fri
  • 28°C
  • 16°C
  • Sat
  • 27°C
  • 18°C
  • Sun
  • 30°C
  • 17°C
  • Tue
  • 31°C
  • 14°C
  • Wed
  • 31°C
  • 13°C
  • Thu
  • 31°C
  • 12°C
  • Fri
  • 33°C
  • 15°C
  • Sat
  • 34°C
  • 14°C
  • Sun
  • 33°C
  • 15°C
  • Tue
  • 32°C
  • 14°C
  • Wed
  • 22°C
  • 16°C
  • Thu
  • 28°C
  • 16°C
  • Fri
  • 27°C
  • 17°C
  • Sat
  • 24°C
  • 18°C
  • Sun
  • 29°C
  • 16°C
  • Tue
  • 19°C
  • 11°C
  • Wed
  • 19°C
  • 10°C
  • Thu
  • 19°C
  • 9°C
  • Fri
  • 21°C
  • 11°C
  • Sat
  • 20°C
  • 13°C
  • Sun
  • 20°C
  • 13°C

Congo to start using J&J Ebola vaccine in November

The J&J vaccine will complement another vaccine manufactured by Merck, which has been administered to more than 225,000 people.

FILE: It requires two injections eight weeks apart, unlike the Merck vaccine, which requires a single shot. Picture: @WHO/Twitter.

KINSHASA - Health authorities in the Democratic Republic of Congo will introduce a Johnson & Johnson Ebola vaccine in November in the country’s eastern provinces, to counter the current outbreak, they said.

The J&J vaccine will complement another vaccine manufactured by Merck, which has been administered to more than 225,000 people. It requires two injections eight weeks apart, unlike the Merck vaccine, which requires a single shot.

A first batch of 500,000 doses of the J&J vaccine should arrive in Congo next week, the authorities said in a statement. The inoculation process will start in Goma in early November and then be extended to other provinces.

Congolese health authorities had announced the deployment of the vaccine last month but had not specified when the campaign will take place.

Since it first started in August 2018, the Ebola outbreak has killed more than 2,100 people, second only to the 2013-16 outbreak in West Africa that killed more than 11,300.

Comments

EWN welcomes all comments that are constructive, contribute to discussions in a meaningful manner and take stories forward.

However, we will NOT condone the following:

- Racism (including offensive comments based on ethnicity and nationality)
- Sexism
- Homophobia
- Religious intolerance
- Cyber bullying
- Hate speech
- Derogatory language
- Comments inciting violence.

We ask that your comments remain relevant to the articles they appear on and do not include general banter or conversation as this dilutes the effectiveness of the comments section.

We strive to make the EWN community a safe and welcoming space for all.

EWN reserves the right to: 1) remove any comments that do not follow the above guidelines; and, 2) ban users who repeatedly infringe the rules.

Should you find any comments upsetting or offensive you can also flag them and we will assess it against our guidelines.

EWN is constantly reviewing its comments policy in order to create an environment conducive to constructive conversations.

comments powered by Disqus